Ratings T&L Co., Ltd.

Equities

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-16 EDT			5-day change	1st Jan Change
67,500 ^KRW	-4.66%		+14.41%	+68.75%

2023	Tranche Update on T&L Co., Ltd.'s Equity Buyback Plan announced on June 15, 2022.	CI
2023	Tranche Update on T&L Co., Ltd.'s Equity Buyback Plan announced on June 15, 2022.	CI

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
For several months, analysts have been revising their EPS estimates roughly upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.

With an enterprise value anticipated at 3894.08 times the sales for the current fiscal year, the company turns out to be overvalued.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is not the most generous with respect to shareholders' compensation.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the past year, analysts have significantly revised downwards their profit estimates.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

	1st Jan change	Capi.	ESG Refinitiv
T&L CO., LTD.	+68.75%	403M	-
ABBOTT LABORATORIES	-5.43%	181B	C+
MEDTRONIC PLC	+4.30%	114B	C
BECTON, DICKINSON AND COMPANY	-3.09%	68.29B	A
DEXCOM, INC.	+5.86%	52.24B	B-
CENCORA, INC.	+8.15%	44.3B	B-
HOYA CORPORATION	+7.52%	42.73B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+25.54%	32.52B	B
TERUMO CORPORATION	+17.85%	26.02B	A-
WEST PHARMACEUTICAL SERVICES, INC.	+1.00%	25.91B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality